Cellosaurus logo
expasy logo

Cellosaurus Mel1617-MR (CVCL_DG53)

[Text version]
Cell line name Mel1617-MR
Synonyms MEL1617-MR
Accession CVCL_DG53
Resource Identification Initiative To cite this cell line use: Mel1617-MR (RRID:CVCL_DG53)
Comments Population: Caucasian.
Selected for resistance to: ChEBI; CHEBI_75998; Trametinib (Mekinist; GSK1120212).
Omics: Variations; Array-based CGH.
Sequence variations
  • Gene deletion; HGNC; HGNC:1787; CDKN2A; Zygosity=Homozygous (from parent cell line).
  • Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line).
Disease Cutaneous melanoma (NCIt: C3510)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Parent: CVCL_DG51 (Mel1617)
Sex of cell Male
Age at sampling 22Y
Category Cancer cell line
Publications

PubMed=24055054; DOI=10.1016/j.celrep.2013.08.023; PMCID=PMC3956616
Jessie Villanueva, Jeffrey R. Infante, Clemens Krepler, Patricia Reyes-Uribe, Minu Samanta, Hsin-Yi Chen, Bin Li, Rolf K. Swoboda, Melissa Wilson, Adina Vultur, Mizuho Fukunaga-Kalabis ...Show all 28 authors... , Bradley Wubbenhorst, Thomas Y. Chen, Qin Liu, Katrin Sproesser, Douglas J. DeMarini, Tona Morgan Gilmer, Anne-Marie Martin, Ronen Marmorstein, David C. Schultz, David W. Speicher, Giorgos Constantine Karakousis, Wei Xu, Ravi K. Amaravadi, Xiao-Wei Xu, Lynn Mara Schuchter, Meenhard Herlyn, Katherine L. Nathanson; Show fewer authors
Concurrent MEK2 mutation and BRAF amplification confer resistance to BRAF and MEK inhibitors in melanoma.
Cell Rep. 4:1090-1099(2013)

Cross-references
Cell line databases/resources cancercelllines; CVCL_DG53
Encyclopedic resources Wikidata; Q54905153
Gene expression databases GEO; GSM1199181
Polymorphism and mutation databases Progenetix; CVCL_DG53
Entry history
Entry creation13-Jul-2016
Last entry update10-Apr-2025
Version number12